Risiken progressiver multifokaler Leukenzephalopathie

2020 ◽  
Vol 88 (02) ◽  
pp. 70
Keyword(s):  
Progressive Multifokale Leukenzephalopathie ◽  
John Cunningham Virus

Progressive multifokale Leukenzephalopathie (PML) ist eine Erkrankung des zentralen Nervensystems. Sie wird durch den sogenannten John Cunningham Virus (JCV) ausgelöst. Natalizumab, ein Medikament, das bei Multipler Sklerose (MS) eingesetzt wird, erhöht das Risiko für PML. Im Rahmen dieser Studie untersuchten die Autoren, inwiefern risikominimierende Maßnahmen die Inzidenz von PML bei Natalizumab-Patienten beeinflussen.

scholarly journals Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis

2018 ◽  
Vol 76 (9) ◽  
pp. 588-591 ◽  
Author(s):  
Luciana Prats Branco ◽  
Tarso Adoni ◽  
Samira Luisa Apostolos-Pereira ◽  
Joseph Bruno Bidin Brooks ◽  
Eber Castro Correa ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Events ◽  
Progressive Multifocal Leukoencephalopathy ◽  
Immunosorbent Assay ◽  
Treatment Options ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Antibodies ◽  
John Cunningham Virus ◽  
Blood Tests ◽  
Serological Profile

ABSTRACT Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). Objective: To identify the serologic profile of JCV in patients with MS. Methods: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. Results: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. Conclusion: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.

John Cunningham Virus‐induced Cerebellar Granular Cell Neuronopathy in a Patient With MS Treated With Natalizumab

Neurographics ◽  
2016 ◽  
Vol 6 (6) ◽  
pp. 369-371 ◽  
Author(s):  
M. Koob ◽  
L. Kremer ◽  
M. Abu Eid ◽  
J. De Seze ◽  
J.-L. Dietemann
Keyword(s):  
Granular Cell ◽  
John Cunningham Virus

The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case–control study

2020 ◽  
pp. 135245852097182
Author(s):  
Mirla Avila ◽  
Annette Okai ◽  
Smathorn Thakolwiboon ◽  
Collin O’Bryan ◽  
Murali Mohan Reddy Gopireddy ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Case Control Study ◽  
The United States ◽  
Case Control ◽  
Retrospective Case ◽  
John Cunningham Virus ◽  
Long Term Effect ◽  
And Gender ◽  
Multiple Sclerosis Patients ◽  
Control Study

Tonsils are believed to be the initial site of the John Cunningham virus (JCV) infection. The long-term effect of childhood tonsillectomy on JCV status in multiple sclerosis (MS) patients has not been investigated. In this retrospective case–control study, we analyzed data of 144 JCV seropositive cases and 82 JCV seronegative controls from three outpatient MS clinics in the United States. Early tonsillectomy (before the age of 8) was reported among 8 (5.56%) JCV seropositive subjects and 19 (23.17%) controls. Early tonsillectomy was associated with JCV negative status (adjusted odds ratio = 5.39, 95% confidence interval = 2.13–13.62, p < 0.001) independent of age and gender.

Sign in / Sign up

Export Citation Format

Share Document